Zepbound vs. Wegovy: Which GLP-1 Weight Loss Drug Is Right for You?

The demand for prescription weight loss medication has surged over the last few years, putting two massive brand names at the center of attention: Zepbound and Wegovy. If you are considering medical support for chronic weight management, you likely want to know how these medications compare. This guide breaks down their effectiveness, potential side effects, and monthly costs to help you prepare for a conversation with your healthcare provider.

The Basics: Active Ingredients and Manufacturers

To understand how these drugs compare, it helps to know what they are and who makes them.

Wegovy is manufactured by Novo Nordisk. Its active ingredient is semaglutide. The FDA approved Wegovy specifically for chronic weight management in adults in 2021. Later, in 2024, the FDA also approved Wegovy to reduce the risk of major cardiovascular events (like heart attacks and strokes) in adults with cardiovascular disease and obesity.

Zepbound is manufactured by Eli Lilly. Its active ingredient is tirzepatide. The FDA approved Zepbound for chronic weight management in late 2023.

Both medications are prescribed for adults with a Body Mass Index (BMI) of 30 or higher. They can also be prescribed to adults with a BMI of 27 or higher if the patient has at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

How Do These Medications Work?

Both drugs belong to a class of medications called incretin mimetics, but they work slightly differently in your body.

Wegovy is a GLP-1 receptor agonist. It mimics a hormone called glucagon-like peptide-1 (GLP-1). This hormone naturally occurs in your intestines and targets areas of the brain that regulate appetite. By mimicking GLP-1, Wegovy makes you feel full sooner and slows down how quickly your stomach empties food.

Zepbound takes a dual-action approach. It is both a GLP-1 receptor agonist and a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Because it targets two different hormone receptors instead of just one, researchers believe Zepbound has a stronger effect on suppressing appetite and improving how the body breaks down sugar and fat.

Effectiveness: Which Drug Causes More Weight Loss?

When comparing effectiveness, clinical trials show that Zepbound currently holds the edge in total weight loss percentages. Keep in mind that both medications require a reduced-calorie diet and increased physical activity to achieve these results.

The STEP clinical trials for Wegovy showed that adults taking the maximum maintenance dose (2.4 milligrams) lost an average of 15% of their initial body weight over a 68-week period.

The SURMOUNT clinical trials for Zepbound showed even more dramatic results. Adults taking the highest dose of Zepbound (15 milligrams) lost an average of 20.9% of their body weight over 72 weeks. Even those on the lowest maintenance dose (5 milligrams) lost an average of 15% of their body weight.

While Zepbound shows higher average weight loss numbers, Wegovy has the added benefit of its FDA approval for cardiovascular health. If you have a history of heart disease, your doctor might prefer Wegovy for its proven heart protection benefits.

Side Effects: What to Expect

Because both drugs alter how your digestive system processes food, their side effects are incredibly similar. The most common issues are gastrointestinal.

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Stomach pain
  • Fatigue
  • Heartburn

These side effects usually happen when you first start taking the medication or when your doctor increases your dosage. For the vast majority of patients, these stomach issues fade over time as the body adjusts.

Both medications also carry severe but rare risks. These include pancreatitis, gallbladder disease, and kidney problems. Additionally, both Wegovy and Zepbound carry an FDA boxed warning regarding thyroid C-cell tumors. People with a personal or family history of medullary thyroid carcinoma should avoid both of these drugs.

Cost and Insurance Coverage

Cost is often the biggest hurdle for patients seeking these treatments. Without insurance coverage, both drugs come with a high monthly price tag.

Wegovy has a list price of $1,349.02 for a 28-day supply. Zepbound is priced slightly lower, with a list price of $1,059.87 for a 28-day supply.

Insurance coverage varies wildly from plan to plan. Medicare currently does not cover weight loss drugs for the sole purpose of weight loss. However, Medicare may cover Wegovy if you have a history of heart disease, thanks to its cardiovascular FDA approval. Commercial insurance plans sometimes cover these medications, but you will almost always need a prior authorization from your doctor.

To help with costs, both Novo Nordisk and Eli Lilly offer commercial savings cards.

  • If your commercial insurance covers the drug, the manufacturer savings cards can bring your copay down to as low as $25 a month.
  • If your commercial insurance denies coverage, Eli Lilly offers a savings program for Zepbound that drops your out-of-pocket cost to roughly $550 per month.
  • Novo Nordisk has a similar cash-pay savings program for Wegovy that takes up to $500 off the list price.

Furthermore, Eli Lilly recently released single-dose vials of Zepbound for cash-paying patients. These vials are priced at $399 for a month of the 2.5-milligram dose and $549 for a month of the 5-milligram dose.

Dosing and Administration

You take both Wegovy and Zepbound exactly the same way. They are weekly subcutaneous injections (shots given just under the skin).

Both medications come in pre-filled, single-use injection pens. You simply press the pen against your stomach, thigh, or upper arm once a week. You do not have to measure the medicine or handle visible needles with the standard auto-injector pens.

Your doctor will start you on a very low dose of either medication to let your body adjust. Over several months, your doctor will gradually increase the dosage until you reach a maintenance dose.

Frequently Asked Questions

Are Mounjaro and Ozempic the same as Zepbound and Wegovy? Yes and no. Ozempic contains the exact same active ingredient (semaglutide) as Wegovy. Mounjaro contains the exact same active ingredient (tirzepatide) as Zepbound. However, the FDA approved Ozempic and Mounjaro specifically to treat Type 2 diabetes, while Wegovy and Zepbound are specifically branded and approved for weight loss.

Do I have to take these medications forever? Obesity is treated as a chronic condition. Clinical studies show that when patients stop taking either Wegovy or Zepbound, they typically regain the majority of the weight they lost within a year. Most doctors view these as long-term or lifetime medications.

Which drug is easier to find in stock? Both drugs have faced severe nationwide shortages due to incredibly high demand. The FDA frequently lists different dose strengths of both Wegovy and Zepbound on its drug shortage database. Availability changes weekly, and patients often have to call multiple local pharmacies to find their prescribed dose in stock.